title: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
abstract: OBJECTIVE
  The aim of this study was to assess whether amifostine could minimize acute mucositis induced by a very accelerated irradiation regimen in patients with advanced head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  Between May 1996 and February 1998, 26 patients with an inoperable nonmetastatic Stage IV HNSCC were entered in this study. The treatment consisted of very accelerated radiotherapy given 64 Gy in 3.5 weeks. The patients were randomized to receive or not 150 mg/m(2), amifostine (Ethyol, U.S. Bioscience) 15-30 min prior to each radiation session.
  
  
  RESULTS
  Of the 13 patients who received amifostine, definitive interruption of amifostine occurred in 5 cases (38%), due to tolerance problems (vomiting, liver enzyme elevation, generalized erythema). The distribution of Grade 4 mucositis (WHO) was 1 case versus 8 cases, with and without amifostine, respectively. The mean duration of "at least Grade 3" mucositis (WHO) was 25.1 days versus 49.2 days with and without amifostine (p = 0.03). In the amifostine group, 11/13 of the patients required a feeding tube (nasogastric tube or medical gastrostomy), because of acute mucositis, whereas in the control group a feeding tube was necessary in all cases. The mean duration of the use of this feeding tube was 1 month versus 2.5 months with and without amifostine respectively (p < 0.01). Local-regional control was not different between both arms with a median follow-up of 15 months.
  
  
  CONCLUSIONS
  Despite the limited number of patients, this pilot randomized study suggests that amifostine was able to markedly reduce the severity and duration of mucositis induced by very accelerated radiotherapy. However, the tolerance of this twice daily amifostine schedule was relatively poor.
authors.affiliation: Radiation Oncology, Head and Neck Surgery, Villejuif, France. bourhis@igr.fr
authors.forename: J
authors.initials: J
authors.lastname: Bourhis
authors.forename: R
authors.initials: R
authors.lastname: De Crevoisier
authors.forename: B
authors.initials: B
authors.lastname: Abdulkarim
authors.forename: E
authors.initials: E
authors.lastname: Deutsch
authors.forename: A
authors.initials: A
authors.lastname: Lusinchi
authors.forename: B
authors.initials: B
authors.lastname: Luboinski
authors.forename: P
authors.initials: P
authors.lastname: Wibault
authors.forename: F
authors.initials: F
authors.lastname: Eschwege
mesh_terms: D000328:Adult; D000368:Aged; D004999:Amifostine / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D005240:Feasibility Studies; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D013280:Stomatitis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine